Piper Jaffray Downgrades Amylin Pharmaceuticals (AMLN) to Neutral
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Piper Jaffray downgraded Amylin Pharmaceuticals (NASDAQ: AMLN) from Overweight to Neutral, maintains price target of $21.00.
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $15.39 yesterday.
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $15.39 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- DA Davidson Downgrades Blaize Inc. (BZAI) to Neutral
- Northcoast Downgrades Brinker Int'l (EAT) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
